Biogen Inc. and Eisai Co., Ltd. have announced new data confirming the pharmacological effect of LEQEMBI® (lecanemab-irmb), an anti-Aβ protofibril antibody, on neurotoxic Aβ protofibrils in cerebrospinal fluid $(CSF)$. The results were presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference in 2025. The study showed that lecanemab treatment led to a significant increase in total CSF protofibril concentration at 12 months compared to placebo, suggesting target engagement and mobilization of protofibrils from the brain parenchyma into the CSF. This data supports the pharmacodynamic effect of lecanemab in patients with Alzheimer's disease.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biogen Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY37559) on December 02, 2025, and is solely responsible for the information contained therein.